Gemini Therapeutics Completes 60 Patients Enrollment In Lead Candidate Mid-Stage Study In Dry AMD
- Gemini Therapeutics Inc (NASDAQ: GMTX) concludes enrollment in its Phase 2a ReGAtta study evaluating GEM103, a recombinant human complement factor H (CFH), in dry Age-related macular degeneration (AMD) patients with CFH loss-of-function gene variants.
- The 60-subject trial is designed to evaluate safety and tolerability and measures of intraocular pharmacokinetics (PK) and disease-relevant biomarkers. Topline data anticipated in the first half of 2021.
- The FDA granted Fast Track Designation for GEM103 to treat dry AMD in patients with CFH loss of function gene variants.
- Price Action: GMTX shares moved 2.95% higher at 13.27 during market hours on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Age-Related Macular Degeneration Phase 2A TrialBiotech News FDA General
